L19IL2 clinical trials
L19IL2 is named as an intervention in 5 current clinical trials in our Italy, Germany, USA, Spain, France and Poland registers. 3 are recruiting patients now. The most common phase is Phase 2. The lead sponsor is Philogen S.p.A. The most-studied condition is Locally Advanced Basal Cell Carcinoma.
How L19IL2 works
All drug targets →- Fibronectin binding agent Binding agentTarget: FN1 fibronectin 1ChEMBL only
- MelanomaPhase 3
- Basal cell carcinomaPhase 2
- Cutaneous squamous cell carcinomaPhase 2
- Non-small cell lung carcinomaPhase 2
- Skin cancerPhase 2
- Diffuse large B-cell lymphomaPhase 1/2
- Renal cell carcinomaPhase 1/2
- Clear cell renal carcinomaPhase 1
- Colorectal adenocarcinomaPhase 1
- Pancreatic adenocarcinomaPhase 1
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL2109608, CC BY-SA 3.0. The Guide to Pharmacology has no record of this medicine, so its targets rest on ChEMBL alone. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for L19IL2
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of L19IL2
5 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with L19IL2
9 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Philogen S.p.A | 5 |
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in Italy | 5 | 3 |
| Clinical trials in Germany | 3 | 2 |
| Clinical trials in USA | 2 | 2 |
| Clinical trials in Spain | 1 | 1 |
| Clinical trials in France | 1 | 0 |
| Clinical trials in Poland | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about L19IL2 trials
How many clinical trials are testing L19IL2?
5 current trials in our Italy, Germany, USA, Spain, France and Poland registers name L19IL2 as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are L19IL2 trials recruiting patients?
Yes. 3 of the 5 trials are recruiting: 3 with sites in Italy, 2 with sites in Germany, 2 with sites in USA and 1 with sites in Spain. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors L19IL2 clinical trials?
The lead sponsor is Philogen S.p.A. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how L19IL2 works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how L19IL2 works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists L19IL2 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.